A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Advanced Glioblastoma|Advanced Colorectal Cancer|Advanced Triple-negative Breast Cancer|Advanced Non-small Cell Lung Cancer
Interventions: DRUG: ONC201
Sponsor: Chimerix